Atlas Trials

Cholangiocarcinoma Non-resectable

20 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Cholangiocarcinoma Non-resectable

RecordFirmDate
DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma (NCT06194695)Ze-yang Ding, MD2022-02-01
Photodynamic Therapy for Cholangiocarcinoma (NCT04860154)Hepatopancreatobiliary Surgery Institute of Gansu Province2021-04-17
TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors (NCT06487663)Tianjin Medical University Cancer Institute and Hospital2020-10-27
Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma (NCT03364530)University Hospital, Montpellier2018-06-11
Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients (NCT03473574)AIO-Studien-gGmbH2018-05-02
A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma (NCT03377179)RedHill Biopharma Limited2018-03-07
Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated With Gemcitabine-based Therapies (NCT03043547)AIO-Studien-gGmbH2017-10-24
Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma (NCT03267940)Halozyme Therapeutics2017-10-02
RFA RCT for Pancreatic or Bile Duct Cancer (NCT02166190)Weill Medical College of Cornell University2014-06-01

Track Cholangiocarcinoma Non-resectable automatically

Every clearance here is in the API, with alerts when new ones post.